Hospital
White Mountain Regional Medical Center
White Mountain Regional Medical Center was paid $6.92M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 22% of everything it billed.
33Billing provider infoWHITE MOUNTAIN REGIONAL MEDICAL CENTER
SPRINGERVILLE, AZ 85938
SPRINGERVILLE, AZ 85938
33aNPI1699766592assigned 10/31/2005
33bProvider typeCritical Access Hospital
28Total paid$6.92M
24GClaims133,426
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arizona
Rank by total paid#8 of 15
Median peer was paid$6.92M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16,903 | $604K | |
| 2019 | 15,621 | $621K | |
| 2020 | 15,715 | $620K | |
| 2021 | 20,843 | $778K | |
| 2022 | 23,623 | $1.20M | |
| 2023 | 22,299 | $1.43M | |
| 2024incomplete | 18,422 | $1.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 22% | 2,431 | 2,077 | $1.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 11,001 | 9,867 | $1.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 6,406 | 5,500 | $979K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 7,353 | 6,732 | $953K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.1% | 543 | 474 | $422K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.4% | 850 | 795 | $372K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.8% | 4,688 | 4,313 | $329K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 1,410 | 1,022 | $202K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 2,427 | 1,936 | $100K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 484 | 402 | $99K |
| 80053 | Comprehensive metabolic panel | 1.3% | 7,843 | 6,614 | $91K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,656 | 832 | $60K |
83 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 475 | $57K |
| 86328 | <1% | 1,464 | $54K | |
| 95065 | <1% | 2,101 | $45K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 802 | $40K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,114 | $40K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,631 | $39K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,142 | $28K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,321 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 475 | $16K |
| 97161 | <1% | 141 | $14K | |
| 73630 | <1% | 270 | $12K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,554 | $11K |
| 72110 | <1% | 64 | $9K | |
| 80320 | <1% | 995 | $8K | |
| 73562 | <1% | 119 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,794 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,715 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 38 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,576 | $6K |
| 73030 | <1% | 125 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,720 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,825 | $4K |
| 73610 | <1% | 43 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 550 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 208 | $3K |
| 80306 | <1% | 1,292 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 94 | $3K |
| 84484 | <1% | 1,736 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,453 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,439 | $2K |
| 73130 | <1% | 28 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 214 | $2K |
| 94664 | <1% | 652 | $2K | |
| 96376 | <1% | 476 | $1K | |
| 73110 | <1% | 59 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,618 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 120 | $908.42 |
| 83880 | <1% | 140 | $760.38 | |
| 83690 | <1% | 1,885 | $717.26 | |
| 84703 | <1% | 1,431 | $695.15 | |
| 97032 | <1% | 1,228 | $572.61 | |
| 80061 | Lipid panel | <1% | 658 | $523.35 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 542 | $479.97 |
| 87081 | <1% | 262 | $464.08 | |
| 81002 | <1% | 3,118 | $423.05 | |
| 85610 | <1% | 1,164 | $357.01 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,464 | $341.87 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 63 | $323.48 |
| 87899 | <1% | 550 | $310.19 | |
| 81000 | <1% | 1,553 | $301.96 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 281 | $277.73 |
| 85379 | <1% | 429 | $270.88 | |
| 83605 | <1% | 365 | $214.55 | |
| 85730 | <1% | 453 | $197.89 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 186 | $196.37 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,247 | $191.27 |
| 83735 | <1% | 574 | $187.79 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,670 | $170.34 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 973 | $169.44 |
| 85027 | <1% | 228 | $112.61 | |
| 85007 | <1% | 233 | $86.89 | |
| 82550 | <1% | 68 | $57.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 571 | $56.46 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 181 | $48.73 |
| 94760 | <1% | 31 | $40.78 | |
| 84439 | <1% | 99 | $25.66 | |
| 87280 | <1% | 98 | $21.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 61 | $21.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 366 | $16.79 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $7.36 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 30 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 48 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 45 | $0.00 |
| 93000 | 0% | 65 | $0.00 | |
| 84480 | 0% | 16 | $0.00 | |
| 87040 | 0% | 17 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 380 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 12 | $0.00 |
| 77003 | 0% | 13 | $0.00 | |
| 80305 | 0% | 16 | $0.00 | |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 22 | $0.00 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBABERS, WESLEY (CEO)